MRNS Deadline: MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit

The Rosen Law Firm is investigating the Allegations that Marinus Pharmaceuticals, Inc. (MRNS) Misled Investors Regarding its Business Operations. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. To join the Marinus class action, go to https://rosenlegal.com/submit-form/?case_id=25735 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected]. Plaintiff alleges that on May 8, 2024, Fierce Biotech published an article which illustrated the impact on t ...